Genentech And Roche Showcase Trontinemab, NLRP3 Inflammasome Research And Blood-Based Diagnostics Across Integrated Pharmaceutical And Diagnostics Portfolio At AAIC
هوفمان-لا روش ADR
هوفمان-لا روش
ROCHE HOLDINGS AG
ROCHE HOLDINGS AG RHHBY | 0.00 | |
ROCHE HOLDINGS AG RHHBF | 0.00 | |
ROCHE HOLDINGS AG RHHVF | 0.00 |
- Five oral presentations in a Featured Research Session will highlight trontinemab, including new long-term data from Phase Ib/IIa Brainshuttle AD study and design of Phase III PrevenTRON study in preclinical Alzheimer’s
- New data on Roche’s CE mark Elecsys pTau217 blood test will be presented on its use for Alzheimer's diagnosis in both primary and secondary care